MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00277-024-06038-7

Медицинская библиотека · Annals of hematology · 2024

Health-related quality of life benefits of arsenic trioxide in patients with non-high-risk acute promyelocytic leukemia are sustained over time: long-term results of the GIMEMA APL0406 trial.

Efficace Fabio, Sparano Francesco, Breccia Massimo, Greco Corinna, Carluccio Paola, Borlenghi Erika, Salutari Prassede, Levato Luciano, Baldi Thomas, Mancini Valentina, Finizio Olimpia, Autore Francesco, Fazi Paola, Platzbecker Uwe, Vignetti Marco, Voso Maria Teresa

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПеревод пока не подготовлен

Аннотация

Very limited evidence is available on the long-term health-related quality of life (HRQoL) of patients with acute promyelocytic leukemia (APL) treated with arsenic trioxide (ATO). We performed an extended follow-up of the APL0406 randomized controlled trial to investigate HRQoL of patients treated with either ATO or chemotherapy. A secondary objective was to describe the prevalence of clinically important problems and symptoms of these patients by type of treatment. Overall, 117 patients were included in this analysis after a median follow-up of 10 years (IQR 8-11) since diagnosis. Of these, 60 (51.3%) were treated with ATO, and 57 (48.7%) with chemotherapy. A statistically significant and clinically relevant difference, favoring patients treated with ATO, was found in 2 of the 3 main prespecified EORTC QLQ-C30 scales, that is, cognitive functioning (∆ = 7.7; 95% CI 0.5 to 14.9; p = 0.036) and fatigue (∆ = -9.4; 95% CI -17.9 to -0.8; p = 0.031). The prevalence of clinically important problems and symptoms tended to be slightly higher in patients treated with chemotherapy. These findings suggest that previously observed HRQoL advantages of ATO therapy of patients included in the APL0406 trial are sustained over the long-term period. This study was registered at ClinicalTrials.gov (NCT03096496).

Для цитирования: Efficace Fabio, Sparano Francesco, Breccia Massimo, Greco Corinna, Carluccio Paola, Borlenghi Erika, Salutari Prassede, Levato Luciano, Baldi Thomas, Mancini Valentina, Finizio Olimpia, Autore Francesco, Fazi Paola, Platzbecker Uwe, Vignetti Marco, Voso Maria Teresa. Health-related quality of life benefits of arsenic trioxide in patients with non-high-risk acute promyelocytic leukemia are sustained over time: long-term results of the GIMEMA APL0406 trial.. Annals of hematology. 2024. DOI: 10.1007/s00277-024-06038-7.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.